ArticleScientific reports2021
Distinctive detection of insulinoma using [
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- [Endocrine journal · 2026Review
- Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.Diabetes · 2026Article
- Case Report: A case of occult insulinoma localized by [Frontiers in endocrinology · 2025Article
- Hypovascular insulinoma with reduced microvessel density on histopathology: a case report.Diabetology international · 2024Article
- Noninvasive evaluation of donor and native pancreases following simultaneous pancreas-kidney transplantation using positron emission tomography/computed tomography.Journal of diabetes investigation · 2023Article
- Unmasked insulinoma occasioned by severe hypoglycemic coma immediately postpartum: a case report.BMC endocrine disorders · 2023Article
- Noninvasive quantitative evaluation of viable islet grafts usingFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Theranostic in GLP-1R molecular imaging: challenges and emerging opportunities.Frontiers in molecular biosciences · 2023Review
- Article
- New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.Current treatment options in oncology · 2022Review
- Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan.Journal of diabetes investigation · 2022Article
- Noninvasive Evaluation of GIP Effects on β-Cell Mass Under High-Fat Diet.Frontiers in endocrinology · 2022Article
- The Current State of Beta-Cell-Mass PET Imaging for Diabetes Research and Therapies.Biomedicines · 2021Review
- First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Specifying the exact localization of insulinoma remains challenging due to the lack of insulinoma-specific imaging methods. Recently, glucagon-like peptide-1 receptor (GLP-1R)-targeted imaging, especially positron emission tomography (PET), has emerged. Although various radiolabeled GLP-1R agonist exendin-4-based probes with chemical modifications for PET imaging have been investigated, an optimal candidate probe and its scanning protocol remain a necessity. Thus, we investigated the utility of a novel exendin-4-based probe conjugated with polyethylene glycol (PEG) for [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.